Hopewell Therapeutics
Hopewell Therapeutics is dedicated to advancing tissue-targeted lipid nanoparticle (ttLNP) technology to develop next-generation genomic medicines for patients with unmet medical needs. The company focuses on designing, synthesizing, and developing innovative lipid nanoparticles for targeted delivery of genomic medicines, including applications in oncology, infectious diseases, rare genetic diseases, and neurological disorders. With a strong scientific foundation from Tufts University and a robust intellectual property portfolio, Hopewell aims to overcome current drug delivery limitations and bring impactful therapies to patients.
Industries
Nr. of Employees
small (1-50)
Hopewell Therapeutics
Woburn, Massachusetts, United States, North America
Products
Internal preclinical LNP therapeutic candidates (lung-focused pipeline)
Internal development programs using tissue-targeted LNPs initially focused on pulmonary diseases, with exploratory programs in oncology, infectious disease, rare genetic and neurological disorders.
HTX-L01-003
LNP-mRNA systemically delivered to achieve deep and long-lasting B-cell depletion including plasmablast cells in non-human primate model.
HTX-L01-008 (GPC3-CD3)
LNP-mRNA systemically delivered to effectively eliminate tumor cells in an orthotopic hepatocellular carcinoma mouse model.
HTX-L01-003 (CD19-CD3)
LNP-mRNA systemically delivered to achieve deep and long-lasting B-cell depletion including plasmablast cells in non-human primate model.
ttLNP platform
A proprietary platform enabling rational design, high throughput screening, and optimization of lipid nanoparticles with diverse cargoes, including mRNA, siRNA, DNA, gene editing and gene-writing apparatus, for targeted delivery to organs, tissues, and cells.
HTX-L02
Lung-targeting lipid nanoparticle formulated with mRNA encoding GM-CSF, demonstrating highly specific lung delivery with minimal off-target effects and robust protein expression in lung tissue.
Internal preclinical LNP therapeutic candidates (lung-focused pipeline)
Internal development programs using tissue-targeted LNPs initially focused on pulmonary diseases, with exploratory programs in oncology, infectious disease, rare genetic and neurological disorders.
HTX-L01-003
LNP-mRNA systemically delivered to achieve deep and long-lasting B-cell depletion including plasmablast cells in non-human primate model.
HTX-L01-008 (GPC3-CD3)
LNP-mRNA systemically delivered to effectively eliminate tumor cells in an orthotopic hepatocellular carcinoma mouse model.
HTX-L01-003 (CD19-CD3)
LNP-mRNA systemically delivered to achieve deep and long-lasting B-cell depletion including plasmablast cells in non-human primate model.
ttLNP platform
A proprietary platform enabling rational design, high throughput screening, and optimization of lipid nanoparticles with diverse cargoes, including mRNA, siRNA, DNA, gene editing and gene-writing apparatus, for targeted delivery to organs, tissues, and cells.
HTX-L02
Lung-targeting lipid nanoparticle formulated with mRNA encoding GM-CSF, demonstrating highly specific lung delivery with minimal off-target effects and robust protein expression in lung tissue.
Services
Collaborative R&D partnerships to apply tissue-targeted LNP technology for therapeutic programs, including joint preclinical studies and formulation optimization.
Development and execution of analytical workflows (HPLC/UPLC, LC–MS, lipid and RNA assays) and bioassays to support product characterization.
Collaborative R&D partnerships to apply tissue-targeted LNP technology for therapeutic programs, including joint preclinical studies and formulation optimization.
Development and execution of analytical workflows (HPLC/UPLC, LC–MS, lipid and RNA assays) and bioassays to support product characterization.
Expertise Areas
- Lipid nanoparticle delivery platform development
- Ionizable lipid synthesis and formulation chemistry
- Nucleic acid therapeutic encapsulation (mRNA, siRNA, DNA, gene editing)
- Preclinical pharmacology, biodistribution and translational studies
Key Technologies
- Lipid nanoparticle formulation
- Ionizable lipid chemistry
- mRNA/siRNA/DNA encapsulation
- In vivo biodistribution studies in rodents and non-human primates